EN
登录

SaaS平台开发商ODAIA完成C轮融资,以扩大面向制药行业的预测性商业智能规模

ODAIA Raises Series C to Scale Predictive Commercial Intelligence for Pharma

CISION 等信源发布 2026-11-17 21:58

可切换为仅中文


Returning investors and strategic investor PHM back

回归投资者及战略投资者 PHM 回归

ODAIA's next stage of growth

ODAIA的下一个增长阶段

BOSTON

波士顿

,

,

Nov. 17, 2026

2026年11月17日

/PRNewswire/ --

/美通社/ --

ODAIA

奥达亚

, an AI company delivering predictive commercial intelligence for pharma, today announced it has closed a US$15 million Series C financing led by

,一家为制药行业提供预测性商业智能的AI公司,今日宣布已完成由领投的1500万美元C轮融资

Monograph Capital

专著资本

and anchored by strategic investor

并由战略投资者锚定

PHM

PHM

, the leading health media agency in the U.S., part of Publicis Groupe. Investors from ODAIA's earlier rounds are also returning:

,美国领先的健康媒体代理机构,隶属于阳狮集团。ODAIA 早期轮次的投资者也再次参与投资:

BDC Capital

BDC资本

,

,

Flint Capital

弗林特资本

,

,

Innospark Ventures

英诺创投

, and

,和

Graphite Ventures

石墨创投

from its Series A and

从其A轮融资中

Threshold Ventures

阈值创投

and

和

Wittington

威廷顿

Ventures

风险投资

from its Series B. ODAIA will use the capital to grow within the enterprise pharma accounts it already serves and continue innovating its commercial intelligence platform.

从其B轮融资中。ODAIA将利用这笔资金在其已服务的制药企业客户中拓展业务,并持续创新其商业智能平台。

Leading biopharmaceutical companies use ODAIA for commercial intelligence and workflow automations for field and marketing teams across many therapeutic areas. ODAIA predicts patient journeys, uncovers missed Rx opportunities, determines which healthcare professionals (HCPs) to prioritize through which channels, and keeps sales and marketing working from one brand strategy..

领先的生物制药公司利用 ODAIA 获取商业智能,并为跨多个治疗领域的实地团队和营销团队实现工作流自动化。ODAIA 能够预测患者诊疗路径,发掘被遗漏的处方药机会,确定应通过哪些渠道优先覆盖哪些医疗保健专业人士(HCP),并确保销售与营销团队围绕统一的品牌策略协同工作。

'Pharma has proven that AI works in commercial. The hard part now is scaling it,' said

“制药行业已经证明人工智能在商业应用中是可行的。现在的难点在于规模化推广,”他说

Philip Poulidis

菲利普·普利迪斯

, CEO and co-founder of ODAIA. 'Most companies can show results on one brand, and every new brand or therapeutic area still costs another team and another build. ODAIA started by helping field teams decide where to focus. Today our platform is the commercial intelligence infrastructure that scales what's working across brand, marketing, and field teams, and across a company's whole portfolio.

ODAIA 首席执行官兼联合创始人。“大多数公司只能在一个品牌上展示成果,而每个新品牌或治疗领域仍需另配团队并重新搭建体系。ODAIA 起初是帮助现场团队决定聚焦方向。如今,我们的平台已成为商业智能基础设施,能够在品牌、营销和现场团队之间,以及在整个公司产品组合范围内,规模化推广行之有效的做法。”

This round lets us go deeper with the enterprise customers we already serve and, with PHM, bring that infrastructure to more of the industry, faster.'.

“本轮融资使我们能够更深入地服务现有的企业客户,并通过 PHM 将这一基础设施更快推广至更广泛的行业。”

'We have watched the ODAIA team turn predictive AI into decisions that pharma brand and field teams act on every day,' said

“我们见证了 ODAIA 团队将预测性人工智能转化为制药品牌团队和实地团队每天付诸行动的决策,”

Charles Conn

查尔斯·康恩

, co-founder and partner at Monograph Capital, which co-led ODAIA's Series B and led this round. 'The ODAIA team has a track record of helping large and specialty pharma brands reach the physicians whose patients need their therapies most.'

,Monograph Capital 的联合创始人兼合伙人,该公司联合领投了 ODAIA 的 B 轮融资并领投了本轮融资。“ODAIA 团队在帮助大型药企和专科药企品牌触达那些患者最需要其疗法的医生方面,拥有良好的业绩记录。”

One strategy for brand, field, and marketing

品牌、领域与营销的一种策略

Inside most pharma companies, data sits in many systems owned by separate teams, so brand, marketing, and field each work from a different picture of the same physician. Patients get missed, field and digital effort lands in the wrong places, and nobody can say with confidence what is influencing HCP decisions.

在大多数制药公司内部,数据分散在由不同团队拥有的多个系统中,因此品牌、营销和实地团队各自基于对同一位医生的不同认知开展工作。这导致患者被遗漏,实地和数字营销资源投放到错误的地方,且无人能够自信地说明究竟是什么因素在影响医疗卫生专业人士(HCP)的决策。

ODAIA's.

ODAIA的。

commercial intelligence platform

商业智能平台

provides the foundation underneath. It brings disparate data, field sales activity, and digital engagement into one view of each HCP that brand, marketing, and field teams all work from.

提供底层基础。它将分散的数据、实地销售活动和数字互动整合为每个医疗保健专业人士(HCP)的统一视图,供品牌、营销和实地团队共同使用。

Brand teams codify their strategy once in

品牌团队将其战略编纂成文,一旦在

Brand Strategy Studio

品牌战略工作室

, and ODAIA's decision engines turn it into HCP-level choices about who to reach, through which channel, when, and with what message. Extending to a new brand or therapeutic area is a matter of configuration. The platform identifies physicians whose patients are likely to need a therapy, often months before a diagnosis shows up in the data..

,而 ODAIA 的决策引擎将其转化为针对医疗卫生专业人士(HCP)层面的决策,包括确定触达对象、渠道、时机以及信息内容。扩展至新品牌或治疗领域仅需进行配置即可。该平台能够识别出患者可能需要某种疗法的医生,这往往比诊断结果出现在数据中提前数月。

Field Intelligence

现场情报

delivers prioritized call plans to field teams inside their CRM, and

将优先呼叫计划直接推送至现场团队所使用的客户关系管理(CRM)系统中,并

Marketing Intelligence

营销情报

orchestrates individualized HCP journeys across digital and partner channels.

统筹规划跨越数字渠道与合作伙伴渠道的个性化医疗保健专业人士(HCP)旅程。

Every ODAIA recommendation comes with the reasoning behind it, so commercial and compliance teams can see why. Commercial leaders ask questions of their data in plain language and get finished analysis in minutes. The platform continuously measures engagement and prescription lift and feeds the results into the next decision, so teams can adjust as markets change..

每个 ODAIA 建议都附带其背后的推理依据,以便商业和合规团队了解原因。商业领导者可以用自然语言向数据提问,并在几分钟内获得完整的分析结果。该平台持续衡量参与度和处方量提升情况,并将结果输入到下一次决策中,从而使团队能够根据市场变化进行调整。

Alongside the financing,

除融资外,

ODAIA signed a commercial Platform Agreement

ODAIA 签署了一份商业平台协议

that makes PHM, Publicis Groupe's U.S. health media agency, ODAIA's exclusive agency partner in the U.S.

这使得PHM(阳狮集团旗下的美国健康媒体代理商)成为ODAIA在美国的独家代理合作伙伴。

ODAIA continues to work directly with pharma companies, and its platform works alongside the CRM, in-house analytics models, and data infrastructure each brand already uses. The partnership connects signals across digital media and field sales so clients can coordinate HCP engagement across both.

ODAIA 继续与制药公司直接合作,其平台与各品牌已使用的客户关系管理(CRM)系统、内部分析模型和数据基础设施协同运行。该合作伙伴关系打通了数字媒体和实地销售之间的信号,使客户能够协调在这两个渠道上的医疗卫生专业人士(HCP)互动。

Founded out of the University of Toronto in 2018, ODAIA is headquartered in Toronto with an office in Boston. To learn more about ODAIA's commercial intelligence platform, visit

ODAIA于2018年从多伦多大学创立,总部设在多伦多,并在波士顿设有办事处。如需了解更多关于ODAIA商业智能平台的信息,请访问

odaia.ai

odaia.ai

.

。

About ODAIA

关于 ODAIA

ODAIA is the leading AI company delivering predictive commercial intelligence for pharma. Leading biopharmaceutical companies, from top-20 global organizations to specialty innovators, use ODAIA to uncover missed Rx opportunities, determine which HCPs to prioritize through which channels, and coordinate true omnichannel execution across sales and marketing.

ODAIA 是一家领先的 AI 公司,为制药行业提供预测性商业智能。从全球前 20 强的生物制药企业到专业领域的创新者,众多领先的生物制药公司都借助 ODAIA 来发掘被忽视的处方药机会,确定应通过哪些渠道优先覆盖哪些医疗卫生专业人士(HCP),并协调销售与营销团队实现真正的全渠道执行。

By continuously turning HCP and patient signals into real-time actions, ODAIA enables commercial teams to adapt strategy as markets change and activate updated guidance directly within the systems they already use. Learn more at .

通过将医疗保健专业人士(HCP)和患者的信号持续转化为实时行动,ODAIA 使商业团队能够随着市场变化调整策略,并直接在他们已使用的系统中激活更新的指导方案。了解更多,请访问 。

odaia.ai

odaia.ai

.

。

SOURCE ODAIA

来源:ODAIA